The aim of the study was to evaluate retrospectively the efficacy of the chronic hip PJI treatment in 2021, depending on the availability of the results of the preoperative microbiological study, and to determine the factors affecting the treatment outcomes. Material and methods: 86 patients with chronic hip PJI were assigned to groups 1 and 2, respectively, depending on the presence or absence of MBI results of preoperative biomaterials (aspirate and/or tissue biopsy) at the time of first stage. Results: The presence of the final results of the joint contents microbiological examination in the preoperative period did not affect the results of the first stage (p=0.536; OR 1.53, 95% CI 0.43-5.45). An increased risk of treatment failure was associated with presence of acetabular defects types 2C (p=0.042, OR 6.66; 95% CI 1.26-35.2) and 3B (p=0.078, OR 8.1; 95% CI 1.015-64.8), femoral defects type 3A (p=0.021, OR 6.57; 95% CI 1.49-29.01), connective tissue diseases (p=0.062, OR 5.25; 95% CI 1.05-26.2), microbial associations (p=0.02, OR 6.75; 95% CI 1.36-33.44) and Gram-negative bacteria in them (p=0.058, OR 4.2; 95% CI 1.02-17.2). As the number of risk factors increased, the probability of a negative outcome increased significantly (p0.001).Conclusion: microbial associations and the presence of Gram-negative bacteria in them, connective tissue diseases, acetabulum defects types 2C and 3B, femoral defects type 3A, as well as the cumulative number of risk factors in one patient had a significant negative impact on the outcomes of the first step of two-stage hip revision. The results of preoperative biomaterials MBI appear to be of greater importance for the PJI diagnosis than as a criterion for the choice of drugs for etiotropic antibacterial therapy. However, this assumption should be investigated in a larger sample of patients.